Redeye sees that BONESUPPORT is well-equipped to surpass its new 50% 2024e sales growth target, and we positively reconsider our US CERAMENT G open trauma sales rampup. Despite a lower-than-expected EBIT, the coming quarters should allow the company to demonstrate its excellent operating leverage more clearly. We up our fair value range somewhat.